Skip to main content
Fig. 3 | BMC Pharmacology and Toxicology

Fig. 3

From: Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation

Fig. 3

Natural killer cell lytic proteins. Bar graph plots representing in vitro assessment of NK cell lytic proteins. Data is represented as either unstimulated or stimulated with K562 target cells, and treated or untreated with RTX. (a) granzyme A and (b) granzyme B. Data is represented as the percentage of intracellular lytic proteins on the y-axis. Data presented as mean ± standard deviation. * refers to significant difference where p < 0.05. Abbreviations: CFS, chronic fatigue syndrome; Stim, stimulated; RTX, Rituximab; NFC, non-fatigued controls; ME, myalgic encephalomyelitis

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us